Effectiveness of Empagliflozin vs Dapagliflozin for Kidney Outcomes in Type 2 Diabetes
Authors' conclusion
The results of this cohort study suggest that people with type 2 diabetes who initiated treatment with empagliflozin and dapagliflozin had comparable long-term kidney outcomes.
Study context
- Population
- Adults with T2D receiving antihyperglycemic treatment, Denmark, June 1, 2014–October 31, 2020; median age 63 years, 37.5% female, median eGFR 88 mL/min/1.73 m²
- Participants
- 32,819 vs 17,464
- Exposure
- Initiation of empagliflozin vs dapagliflozin
- Empagliflozinn = 32,819
- Dapagliflozinn = 17,464reference
- Outcome
- Kidney outcomes: acute kidney injury, incident CKD (stages G3 to G5 or stage A2 or A3), progression of CKD (≥40% decrease in eGFR from baseline)
- Follow-up
- 6 years
Methodological detailsnationwide, population-based, routinely collected Danish health care data, adjusted for 56 potential confounders, death as competing event, Followed up until outcome, emigration, death, 6 years, or December 31, 2021
- Nationwide
- Population-based
- Routinely collected Danish health care data
- Adjusted for 56 potential confounders
- Death as competing event
- Followed up until outcome, emigration, death, 6 years, or December 31, 2021
Main finding
As reported in the abstract
Kidney outcomes (6-year risks)
Each group vs dapagliflozinEstimate (95% CI)
Empagliflozin
risk ratio (acute kidney injury: 18.2% vs 18.5%) 0.98(0.91–1.06)
Empagliflozin
risk ratio (CKD stages G3 to G5: 11.8% vs 12.1%) 0.97(0.89–1.05)
Empagliflozin
risk ratio (CKD stage A2 or A3: 14.8% vs 14.3%) 1.04(0.93–1.15)
Empagliflozin
risk ratio (CKD progression: 5.3% vs 5.7%) 0.94(0.56–1.58)
Observational data: associations, not effects.
Original publication
Effectiveness of Empagliflozin vs Dapagliflozin for Kidney Outcomes in Type 2 Diabetes. JAMA Intern Med. Published 1 March 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →